OptiNose (OPTN) Revenue & Revenue Breakdown
OptiNose Revenue Highlights
Latest Revenue (Y)
$70.99M
Latest Revenue (Q)
$20.49M
Main Segment (Y)
Product
OptiNose Revenue by Period
OptiNose Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $70.99M | -6.93% |
| 2022-12-31 | $76.28M | 2.18% |
| 2021-12-31 | $74.65M | 51.99% |
| 2020-12-31 | $49.12M | 41.83% |
| 2019-12-31 | $34.63M | 390.18% |
| 2018-12-31 | $7.07M | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $47.50M | 55782.35% |
| 2015-12-31 | $85.00K | - |
OptiNose generated $70.99M in revenue during NA 2023, up -6.93% compared to the previous quarter, and up 1004.77% compared to the same period a year ago.
OptiNose Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $20.49M | 37.70% |
| 2024-03-31 | $14.88M | -25.09% |
| 2023-12-31 | $19.86M | 0.21% |
| 2023-09-30 | $19.82M | 1.90% |
| 2023-06-30 | $19.45M | 64.22% |
| 2023-03-31 | $11.85M | -43.20% |
| 2022-12-31 | $20.86M | 3.87% |
| 2022-09-30 | $20.08M | -2.45% |
| 2022-06-30 | $20.58M | 39.44% |
| 2022-03-31 | $14.76M | -34.43% |
| 2021-12-31 | $22.51M | 3.13% |
| 2021-09-30 | $21.83M | 18.90% |
| 2021-06-30 | $18.36M | 53.49% |
| 2021-03-31 | $11.96M | -26.84% |
| 2020-12-31 | $16.35M | 5.90% |
| 2020-09-30 | $15.44M | 50.27% |
| 2020-06-30 | $10.27M | 45.45% |
| 2020-03-31 | $7.06M | -36.27% |
| 2019-12-31 | $11.08M | -10.62% |
| 2019-09-30 | $12.40M | 85.67% |
| 2019-06-30 | $6.68M | 49.17% |
| 2019-03-31 | $4.48M | 48.06% |
| 2018-12-31 | $3.02M | 58.94% |
| 2018-09-30 | $1.90M | 49.29% |
| 2018-06-30 | $1.27M | 47.28% |
| 2018-03-31 | $865.00K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | - |
OptiNose generated $20.49M in revenue during Q2 2024, up 37.70% compared to the previous quarter, and up 172.97% compared to the same period a year ago.
OptiNose Revenue Breakdown
OptiNose Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $70.99M | $76.28M | $73.65M | $48.37M | $30.40M |
| License | - | - | $1.00M | $750.00K | $4.23M |
Latest
OptiNose's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $20.44M | $14.88M | $39.69M | $19.45M | $11.85M | $20.86M | $20.08M | $20.58M | $14.76M | $22.51M | $21.83M | $18.36M | $10.96M | $15.60M | $15.44M | $10.27M | $7.06M | $11.08M | $8.67M | $6.68M |
| License | - | - | - | - | - | - | - | - | - | - | - | - | $1.00M | - | - | - | - | $3.73M | - | - |
Latest
OptiNose's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (100.00%).
OptiNose Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| PBH | Prestige Consumer Healthcare | $1.13B | $283.55M |
| PAHC | Phibro Animal Health | $977.89M | $273.16M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $188.82M |
| COLL | Collegium Pharmaceutical | $566.77M | $159.30M |
| ANIP | ANI Pharmaceuticals | $486.82M | $148.33M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $91.59M |
| PROC | Procaps Group | $409.92M | $118.41M |
| DVAX | Dynavax | $232.28M | $79.34M |
| EOLS | Evolus | $199.72M | $60.16M |
| KMDA | Kamada | $144.76M | $37.40M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| OPTN | OptiNose | $70.99M | $20.49M |
| CPIX | Cumberland Pharmaceuticals | $39.55M | $9.09M |
| SHPH | Shuttle Pharmaceuticals | - | - |
| RGC | Regencell Bioscience | - | - |